SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) SOL-R is a global, 825-patient, non-inferiority study evaluating repeat dosing of AXPAXLI every six months (Q6M) compared to 2 mg aflibercept, dosed every eight weeks (Q8W) in patients with wet AMD. A third arm evaluating 8 mg aflibercept dosed Q6M is incorporated to ensure the study is adequately masked. The trial is evaluating AXPAXLI versus the current standard of care under the "real world" requirements of a repeat ...

BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that a late-breaking abstract related to the Phase 1 HELIOS study of AXPAXLI (axitinib intravitreal imp ...

Mr. Rao's inducement awards were granted effective as of July 1, 2024. Mr. Rao's inducement awards consist of (i) a non-statutory stock option to purchase up to 20,000 shares of the Ocular's common stock at a per share exercise price equal to the closing price of Ocular's common stock on The Nasdaq Global Market on July 1, 2024, and (ii) a restricted stock unit award representing the right to receive 6,666 shares of Ocular's common stock. The stock option has a ten-year term and is scheduled to vest over fo ...

WORLD CLASS RETINA EXPERTISE AXPAXLI Has Demonstrated Proof-of-Concept in Three Phase 1 trials wAMD Trials Demonstrated Monotherapy Proof-ofConcept and Potential Best–in–class Durability Phase 1 Australia Trial1: Monotherapy Activity Month 9 CSFT: 244µm BCVA: 81 letters (20/25) Month 6 CSFT: 239µm BCVA: 80 letters (20/25) Month 2 CSFT: 236µm BCVA: 74 letters (20/30) Baseline CSFT: 484µm BCVA: 56 letters (20/80) Treatment naïve & experienced patients Treatment naïve & experienced patients Patients received n ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Investor Day Conference Call June 13, 2024 2:00 PM ET Company Participants Bill Slattery - Vice President, Investor Relations Pravin Dugel - Executive Chairman, President and CEO Jeff Heier - Chief Scientific Officer Peter Kaiser - Chief Development Officer Nadia Waheed - Chief Medical Officer Barry Kuppermann - Steinert Professor and Chair, Department, Ophthalmology and Director, Gavin Herbert Eye Institute, UC, Irvine Dilsher Dhoot - Retina Consultants of America Don ...

About Ocular Therapeutix, Inc. 151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024 48-week HELIOS NPDR results show 23.1% of patients in AXPAXLI arm experienced ≥2-step DRSS improvement with no patients experiencing worsening of DRSS or vision threatening complications "2024 has been a time of significant accomplishment for Ocular. To support our mission to become a leader in retinal care, we successfully assembled a 'Retina Dr ...

Ocular's Investor Day will also include KOL roundtable discussions followed by a live Q&A session. In-person attendees are invited to join Ocular leadership and the participating KOLs for a networking reception to conclude the event. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Company's website at investors.ocutx.com. A replay of the webcast will be archived for at least 30 days following the presentation. About Baruch D. Kuppermann, ...

Shidlovski Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company developing innovative eye treatment therapies. OCUL already offers a commercial product called Dextenza for post-surgical ocular inflammation and pain and ocular itching due to allergic conjunctivitis. The drug is a market success with a net product revenue of $57.9 million in 2023. OCUL's pipeline includes Axpaxli, an axitinib intravitreal implant in phase 3 trials for wet age-related macular degeneration (wet AMD) and phase 1 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (St ...

Exhibit 99.1 Ocular Therapeutix™ Reports First Quarter 2024 Results Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, MA, May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeut ...